Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03OFN
|
||||
| Former ID |
DIB011444
|
||||
| Drug Name |
NK-314
|
||||
| Synonyms |
Topoisomerase modulator, Nippon Kayaku
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Phase 1 | [1] | ||
| Company |
Nippon Kayaku Co Ltd
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
[n+]12c3c(c4c(c1CCC2)c(c(cc4)OC)O)ccc1c3cc2c(c1)OCO2.[C<br />l-]
|
||||
| Target and Pathway | |||||
| Target(s) | DNA topoisomerase II | Target Info | Modulator | [2] | |
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020174) | ||||
| REF 2 | NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J Biol Chem. 2008 Aug 29;283(35):23711-20. Epub 2008 Jul 2. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.